• Aucun résultat trouvé

Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial

N/A
N/A
Protected

Academic year: 2021

Partager "Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial"

Copied!
11
0
0

Texte intégral

(1)

HAL Id: hal-01818634

https://hal.umontpellier.fr/hal-01818634

Submitted on 18 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised

controlled, phase 3 trial

Samir Jaber, Catherine Paugam, Emmanuel Futier, Jean-Yves Lefrant, Sigismond Lasocki, Thomas Lescot, Julien Pottecher, Alexandre Demoule,

Martine Ferrandiere, Karim Asehnoune, et al.

To cite this version:

Samir Jaber, Catherine Paugam, Emmanuel Futier, Jean-Yves Lefrant, Sigismond Lasocki, et al..

Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. The Lancet, Elsevier, 2018, 392 (10141), pp.31-40. �10.1016/S0140-6736(18)31080-8�. �hal-01818634�

(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)

Références

Documents relatifs

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low- risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised

Despite the superior efficacy of CPAP in reducing OSA severity, most trials comparing MAD and CPAP have reported similar health outcomes.[4,5] In a recent

Ce questionnaire a été élaboré afin de tester notre principale question « quels sont les freins de l’entrepreneuriat féminin en Algérie » ; le questionnaire

Turning to gradual fiscal consolidation measures, we obtain for SSA and Zone Franc countries a positive and significant effect for the remittances variable, but no significant

The proposed paper describes work towards stan- dards which will be integrated into the existing standards portfolio: ISOTiger (ISO/DIS 24615-2) is building on top of SynAF;

La « révolution maritime », qui fait passer le navire du bois au métal et de la propulsion éolienne à la propulsion par la machine, s’est opérée au XIX e siècle dans les

[r]

On March 19, 2020, Alexion Pharmaceuti- cals, Inc., (Boston, MA, USA), subsequent to physician request and in accordance with relevant national regulatory authorities, provided